LIPOCINE INC. Payments to Acquire Debt Securities, Available-for-sale
LIPOCINE INC. (LPCN) reported Payments to Acquire Debt Securities, Available-for-sale of $20.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $5.02M.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $15.20M, a 199.17% increase year-over-year.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $4.43M, a 54.48% decline year-over-year.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $5.20M, a 7.13% decline year-over-year.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $14.71M, a 55.24% decline from fiscal 2024.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $32.86M, a 43.50% increase from fiscal 2023.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $22.90M, a 49.19% decline from fiscal 2022.
- LIPOCINE INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $45.07M, a 6.91% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $20.22M 10-Q · filed 2026-08-04 | $24.65M derived: sum of 3 quarters · filed 2026-08-04 | $29.85M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $15.20M 10-Q · filed 2026-05-07 | $19.63M derived: sum of 2 quarters · filed 2026-05-07 | $24.83M derived: sum of 3 quarters · filed 2026-05-07 | $24.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.63M derived: sum of 2 quarters · filed 2026-03-10 | $9.63M derived: sum of 3 quarters · filed 2026-08-04 | $14.71M 10-K · filed 2026-03-10 |
| 2025-09-30 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.20M derived: sum of 2 quarters · filed 2026-08-04 | $10.28M 10-Q · filed 2025-11-06 | $20.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.08M 10-Q · filed 2026-08-04 | $14.81M derived: sum of 3 quarters · filed 2026-08-04 | $20.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $5.08M 10-Q · filed 2026-05-07 | $14.81M derived: sum of 2 quarters · filed 2026-05-07 | $20.41M derived: sum of 3 quarters · filed 2026-05-07 | $27.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $15.33M derived: sum of 2 quarters · filed 2026-03-10 | $22.07M derived: sum of 3 quarters · filed 2026-03-10 | $32.86M 10-K · filed 2026-03-10 |
| 2024-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $12.35M derived: sum of 2 quarters · filed 2025-11-06 | $23.13M 10-Q · filed 2025-11-06 | $32.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $17.54M 10-Q · filed 2025-08-05 | $26.90M derived: sum of 3 quarters · filed 2025-08-05 | $31.66M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $10.79M 10-Q · filed 2025-05-08 | $20.15M derived: sum of 2 quarters · filed 2025-05-08 | $24.91M derived: sum of 3 quarters · filed 2025-05-08 | $27.25M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $14.12M derived: sum of 2 quarters · filed 2025-03-13 | $16.46M derived: sum of 3 quarters · filed 2025-03-13 | $22.90M 10-K · filed 2025-03-13 |
| 2023-09-30 | $4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.10M derived: sum of 2 quarters · filed 2024-11-07 | $13.54M 10-Q · filed 2024-11-07 | $25.04M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.78M 10-Q · filed 2024-08-08 | $20.29M derived: sum of 3 quarters · filed 2024-08-08 | $31.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $6.44M 10-Q · filed 2024-05-09 | $17.95M derived: sum of 2 quarters · filed 2024-05-09 | $28.83M derived: sum of 3 quarters · filed 2024-05-09 | $33.61M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $22.39M derived: sum of 2 quarters · filed 2024-03-07 | $27.17M derived: sum of 3 quarters · filed 2024-03-07 | $45.07M 10-K · filed 2024-03-07 |
| 2022-09-30 | $10.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $15.66M derived: sum of 2 quarters · filed 2023-11-08 | $33.57M 10-Q · filed 2023-11-08 | $44.68M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $4.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $22.68M 10-Q · filed 2023-08-10 | $33.80M derived: sum of 3 quarters · filed 2023-08-10 | $35.23M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $17.91M 10-Q · filed 2023-05-11 | $29.02M derived: sum of 2 quarters · filed 2023-05-11 | $30.45M derived: sum of 3 quarters · filed 2023-05-11 | $31.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $11.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $12.55M derived: sum of 2 quarters · filed 2023-03-10 | $13.98M derived: sum of 3 quarters · filed 2023-03-10 | $48.42M 10-K · filed 2023-03-10 |
| 2021-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $2.86M derived: sum of 2 quarters · filed 2022-11-09 | $37.31M 10-Q · filed 2022-11-09 | $37.31M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $35.88M 10-Q · filed 2022-08-08 | $35.88M derived: sum of 3 quarters · filed 2022-08-08 | $37.72M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $34.44M 10-Q · filed 2022-05-09 | $34.44M derived: sum of 2 quarters · filed 2022-05-09 | $36.29M derived: sum of 3 quarters · filed 2022-05-09 | $40.31M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $1.85M derived: sum of 2 quarters · filed 2022-03-09 | $5.87M derived: sum of 3 quarters · filed 2022-03-09 | $6.32M 10-K · filed 2022-03-09 |
| 2020-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.87M derived: sum of 2 quarters · filed 2021-11-10 | $6.32M 10-Q · filed 2021-11-10 | $8.06M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $4.47M 10-Q · filed 2021-08-05 | $6.21M derived: sum of 3 quarters · filed 2021-08-05 | $8.79M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $447.78K 10-Q · filed 2021-05-06 | $2.19M derived: sum of 2 quarters · filed 2021-05-06 | $4.77M derived: sum of 3 quarters · filed 2021-05-06 | $10.52M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $4.32M derived: sum of 2 quarters · filed 2021-03-11 | $10.07M derived: sum of 3 quarters · filed 2021-03-11 | $16.85M 10-K · filed 2021-03-11 |
| 2019-09-30 | $2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $8.33M derived: sum of 2 quarters · filed 2020-11-10 | $15.11M 10-Q · filed 2020-11-10 | $19.96M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $12.53M 10-Q · filed 2020-08-06 | $17.38M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | $6.78M 10-Q · filed 2020-05-07 | $11.64M derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $25.55M 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $20.70M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |